Immunotherapy of rheumatic diseases--practice and prospects.
Present treatments for rheumatic diseases are both toxic to patients and largely ineffective in modifying the disease process. This report, based on a meeting recently held in London, investigates how far recent molecular and immunological advances can be converted into more effective, less toxic and, above all, more specific therapies.
Kingsley
G
G
Rheumatology Unit, United Medical School, Guy's Hospital, London, UK.
Panayi
G
G
Lanchbury
J
J
D016207:Cytokines / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D012216:Rheumatic Diseases / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination
D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D011948:Receptors, Antigen, T-Cell